NASDAQ:BLUE
bluebird bio Stock News
$1.03
-0.0200 (-1.90%)
At Close: May 17, 2024
bluebird bio to Separate Oncology Business into Independent Company
06:30am, Monday, 11'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly tr
bluebird bio: One Of My Top Picks For 2021
02:40pm, Wednesday, 06'th Jan 2021
bluebird had a rough 2020 but we are quickly approaching several key catalysts in 2021 that will transform the company's outlook and possibly inject some momentum into the share price. ZYNTEGLO has co
bluebird bio Inc., Undervalued Acquisition Candidate
11:08am, Wednesday, 06'th Jan 2021
I estimate the fair value for BLUE between $5-7 billion based on similar acquisitions. 2021 could be an inflection point with the anticipated approval of the company's multiple myeloma treatment.
3 Top Biotech Buyout Candidates in 2021
06:09am, Monday, 04'th Jan 2021
Big drugmakers could be attracted to these smaller players with promising pipelines.
3 FDA Dates Biotech Investors Should Circle in 2021
07:34am, Thursday, 24'th Dec 2020
These biotech stocks could sink or soar following some important approval decisions slated for the new year.
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
10:00am, Thursday, 17'th Dec 2020
Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).
ASH Annual Meeting: Drugmakers Battle for Multiple Myeloma
11:44am, Sunday, 13'th Dec 2020
Targeting BCMA is all the rage, but who will come out on top?
Here's the Hot Target for Multiple Myeloma Drugs
03:44pm, Saturday, 12'th Dec 2020
Drugmakers are targeting B-cell maturation antigen in different ways.
Watch Out bluebird bio, CRISPR Is on Your Heels
03:39pm, Saturday, 12'th Dec 2020
The battle for beta thalassemia and sickle cell disease patients is heating up.
3 Stocks That Are Giving Their Investors Coal in Their Stockings
07:20am, Saturday, 12'th Dec 2020
Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.
Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officer
08:00am, Tuesday, 08'th Dec 2020
SEATTLE--(BUSINESS WIRE)-- #shapelife--Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appoin
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from Group C of its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin™ gene therapy (bb1111)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #ASH2020--BMS and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myelom
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-1
